Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
71.50    0.50 (0.70%)
Bid:
71.20
Ask:
74.00
Spread: 2.80 (3.933%)
Market Cap: £684.32m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

AGM Trading Update

10 Jul 2025 07:00

RNS Number : 4225Q
Dr. Martens PLC
10 July 2025
 

10 July 2025

Dr. Martens plc - AGM Trading Update

Trading in line with expectations; FY26 guidance unchanged

 

Dr. Martens plc will hold its AGM at 09.30am today at 1-11 Hawley Crescent, Camden, London, NW1 8NP, and also provides the following update.

Trading since the start of this financial year has been in line with expectations and all guidance for FY26 remains unchanged. On a regional basis, we have continued to see positive trading in our Americas Direct to Consumer ("DTC") channel, driven by full price sales, particularly in Retail. Our EMEA DTC business remains more variable, with our UK business in particular continuing to experience a challenging trading backdrop. Our APAC business continues to show good growth, with a particularly strong performance in South Korea driven by our well-established shoes category here.

Looking forward, the Autumn/Winter order books globally are healthy. The EMEA order book is up year-on-year, whilst the Americas order book is broadly in line year-on-year and importantly is based on a much wider product range than previously. As ever, our performance will be H2-weighted, particularly from a profit perspective.

We are focused on embedding our new consumer-first Levers for Growth strategy, which we outlined at our results on 5 June and which builds on the work undertaken in FY25 to stabilise the business. The strategy capitalises on the clear strengths of the business today and taps into the significant new markets and profit pools that are available to us. It is centred on engaging more consumers, driving more product purchase occasions, curating market-right distribution and simplifying the operating model. Further details on our early progress in these areas will be shared at our first half results in November.

 

 

Enquiries

 

Investors and analysts

Bethany Barnes, Director of Investor Relations +44 7825 187465 bethany.barnes@drmartens.com

Beth Fionda, Investor Relations Manager beth.fionda@drmartens.com

 

Press

Sodali & Co

Ludo Baynham-Herd

Oliver Banks drmartens@client.sodali.com

+44 207 250 1446

 

 

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. "Docs" or "DMs" were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over 60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and wholesale channels, and in addition to its world-renowned "1460" boot its product segments span shoes including the 1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and accessories. Further information can be found at https://www.drmartensplc.com/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSSAFIUEISEDW
Date   Source Headline
11th Jul 202411:05 amRNSResult of AGM
11th Jul 20247:00 amRNSAGM Trading Update
1st Jul 202412:44 pmRNSTotal Voting Rights
18th Jun 202412:00 pmRNSBlock listing Interim Review
14th Jun 202412:51 pmRNSDirector/PDMR Shareholding
14th Jun 202412:50 pmRNSDirector/PDMR Shareholding
12th Jun 20244:35 pmRNSHolding(s) in Company
12th Jun 20244:35 pmRNSTechnical change in Permira ownership structure
12th Jun 20244:35 pmRNSHolding(s) in Company
12th Jun 202412:20 pmRNSDirector/PDMR Shareholding
12th Jun 20249:00 amRNSAnnual Financial Report
3rd Jun 20249:00 amRNSDirector/PDMR Shareholding
3rd Jun 20249:00 amRNSCompany Secretary Change
31st May 20247:00 amRNSTotal Voting Rights
30th May 20247:00 amRNSFY24 Results
14th May 20241:24 pmRNSDirector/PDMR Shareholding
10th May 20247:00 amRNSCFO start date - update
1st May 20244:14 pmRNSTotal Voting Rights
16th Apr 20247:00 amRNSCEO succession
16th Apr 20247:00 amRNSFY24 trading and FY25 outlook update
12th Apr 20243:13 pmRNSDirector/PDMR Shareholding
28th Mar 20245:56 pmRNSTotal Voting Rights
12th Mar 20243:50 pmRNSDirector/PDMR Shareholding
1st Mar 202411:19 amRNSTotal Voting Rights
27th Feb 20247:00 amRNSCFO appointment update
14th Feb 20244:10 pmRNSDirector/PDMR Shareholding
5th Feb 20242:13 pmRNSDirector/PDMR Shareholding
1st Feb 202410:40 amRNSTotal Voting Rights
25th Jan 20247:00 amRNSQ3 FY24 Trading Statement
12th Jan 20241:58 pmRNSDirector/PDMR Shareholding
2nd Jan 202410:13 amRNSTotal Voting Rights
15th Dec 20236:20 pmRNSTransaction in Own Shares
14th Dec 20236:15 pmRNSTransaction in Own Shares
13th Dec 20236:02 pmRNSTransaction in Own Shares
12th Dec 20236:24 pmRNSTransaction in Own Shares
12th Dec 20231:42 pmRNSDirector/PDMR Shareholding
11th Dec 20236:04 pmRNSTransaction in Own Shares
8th Dec 20236:16 pmRNSTransaction in Own Shares
7th Dec 20236:23 pmRNSTransaction in Own Shares
6th Dec 20236:08 pmRNSTransaction in Own Shares
5th Dec 20236:20 pmRNSTransaction in Own Shares
4th Dec 20236:29 pmRNSTransaction in Own Shares
1st Dec 20236:20 pmRNSTransaction in Own Shares
1st Dec 20232:08 pmRNSHolding(s) in Company
1st Dec 20238:00 amRNSBlock listing Interim Review
30th Nov 20234:08 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSHalf-year Report
20th Nov 20236:07 pmRNSTransaction in Own Shares
17th Nov 20236:21 pmRNSTransaction in Own Shares
16th Nov 20236:23 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.